trending Market Intelligence /marketintelligence/en/news-insights/trending/vh-5sow0zflqopu2-9sexw2 content esgSubNav
In This List

Edwards Lifesciences prevails in US review of Boston Scientific's patent claims

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Edwards Lifesciences prevails in US review of Boston Scientific's patent claims

The U.S. Patent and Trademark Office ruled in favor of Edwards Lifesciences Corp. in an inter partes review of Boston Scientific Corp.'s claims regarding its transcatheter heart valve.

The patent office decided that all the claims asserted against Edwards Lifesciences were invalid.

Boston Scientific had filed a patent case against Edwards Lifesciences in Delaware in 2016.

In March 2017, a U.K. patent court decided that a patent related to Edwards Lifesciences' Sapien 3 transcatheter heart valve infringed on a Boston Scientific patent.

Then in March 2017, a German district court ruled that Edwards Lifesciences' Sapien 3 transcatheter heart valve infringed on two patents of Boston Scientific's related to the seals for transcatheter heart valves.

Meanwhile, Edwards Lifesciences has asserted three of its own foundational transcatheter heart valve patents against Boston Scientific. These remain unaffected by the US patent office's decision and will continue to trial, which is expected later in 2018.

Irvine, Calif.-based Edwards Lifesciences provides products and technologies to treat heart diseases and for critical care monitoring.